Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UBX-362
- Development stage
- Preclinical
- Lead developer
- Ubix Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
UBX-362: sourced facts only. name: "UBX-362 exhibits strong degradation activity against BCR-ABL1 proteins in CML cell lines." [DOI:10.1158/1538-7445.am2025-5591]; target: "UBX-362 exhibits strong degradation activity against BCR-ABL1 proteins in CML cell lines." [DOI:10.1158/1538-7445.am2025-5591]; developer: "Ubix Therapeutics, Seoul, Republic of Korea." [DOI:10.1158/1538-7445.am2025-5591]; modality: "In this study, we report the identification of potent, orally efficacious BCR-ABL1 PROTACs." [DOI:10.1158/1538-7445.am2025-5591]; stage: "Oral administration of UBX-362 significantly reduced BCR-ABL1 protein levels in tumor tissue and robustly inhibited tumor growth in a CML CDX mouse model." [DOI:10.1158/1538-7445.am2025-5591]
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)
Beyond the preview
Go deeper on UBX-362.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UBX-362.